Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Immuno-Oncology and Vaccines

The Immuno-oncology (I-O) Focus on VJHemOnc is supported by Johnson & Johnson. This supporter has no influence over the production of the content.

Therapeutic and prophylactic vaccines are an exciting upcoming area in hematology-oncology. In solid tumors, there have been many clinical trials1-6 and several approvals7,8. Now moving forward in the hemonc space, vaccines offer the prospect of long-term responses with limited side effects9.

Personalized dendritic cell vaccines for acute leukemias and multiple myeloma have yielded promising results in clinical trials10-13. There are also vaccines in trials for chronic lymphocytic leukemia14,15, chronic myeloid leukemia and other myeloid malignancies16-19, myeloproliferative neoplasms20, and myelodysplastic syndromes21. Another personalized vaccine has been investigated for the treatment of follicular lymphoma, mantle cell lymphoma and Waldenstrom’s macroglobulinemia22,23.

  1. Melero I, Gaudernack G, Gerritsen W, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014 Sep; 11(9): 509-24.
  2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012 Dec 4. Identifier NCT01740297. Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01740297
  3. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Mar 17. Identifier NCT02390063. Vaccination in Prostate Cancer (VANCE); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02390063
  4. Tanyi JL, Bobisse S, Ophir E, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018 Apr 11; 10(436).
  5. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 28. Identifier NCT02348320. Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02348320
  6. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 Mar 20. Identifier NCT01814813. Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery; [cited 2018 Aug 29]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01814813
  7. FDA.gov [Internet]. PROVENGE (sipuleucel-T); [updated 2018 Feb 20]; [cited 2018 Aug 29]. Available from: https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210012.htm
  8. FDA.gov [Internet]. Human Papillomavirus Vaccine; [updated 2018 Feb 20]; [cited 2018 Aug 29]. Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172678.htm
  9. VJHemOnc.com [Internet]. Using vaccines to impart a long-term response in lenalidomide-treated MM; c2017-06; [cited 2018 Aug 29]. Available from: https://www.vjhemonc.com/video/ssaigcq_dkk-using-vaccines-to-impart-a-long-term-response-in-lenalidomide-treated-mm/
  10. VJHemOnc.com [Internet]. Personalized dendritic cell vaccine for acute leukemia and multiple myeloma; c2018-04; [cited 2018 Aug 29]. Available from: https://www.vjhemonc.com/video/9zooz_nhvx8-personalized-dendritic-cell-vaccine-for-acute-leukemia-and-multiple-myeloma/
  11. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 Apr 5. Identifier NCT02728102. Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02728102
  12. Anguille S, Van de Velde AL, Smits EL, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017 Oct; 130(15): 1713-1721.
  13. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2004 May 21. Identifier NCT00002787. Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT00002787
  14. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 Nov 5. Identifier NCT01976520. Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01976520
  15. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 May 11. Identifier NCT01351896. Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01351896
  16. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Sep 7. Identifier NCT02543749. DC Vaccination in CML; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02543749
  17. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2007 Apr 27. Identifier NCT00466726. Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML0206); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT00466726
  18. Ottensmeier C, Bowers M, Hamid D, et al. Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). Efficacy Mech Eval. 2016 Apr.
  19. Qazilbash MH, Wieder E, Thall PF, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017 Mar; 31(3) :697-704.
  20. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 June 25. Identifier NCT03566446. CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03566446
  21. Griffiths EA, Srivastava P, Matsuzaki J, et al. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clin Cancer Res. 2018 Mar 1; 24(5): 1019-1029.
  22. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2004 Sep 17. Identifier NCT00091676. Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma (BiovaxID); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT00091676
  23. Neelapu SS, Kwak LW, Kobrin CB. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med. 2005 Sep; 11(9): 986-91.
View overview page
1:18
Immunotherapeutic approaches in CALR-mutated MPNs
John Mascarenhas • 9 Sep 2023
4:49
Best practices for vaccines after SCT and cellular therapy & the role of pharmacists in this process
Susie Long • 9 Feb 2023
3:15
The importance of monitoring COVID-19 in patients with Waldenström’s macroglobulinemia
Lee Greenberger • 31 Oct 2022
1:54
The potential role of cellular therapies and vaccines in the future treatment of MPNs
Srdan Verstovsek • 28 Sep 2022
4:59
Incidence, prevention, and management of infections in multiple myeloma
Heinz Ludwig • 26 Aug 2022
2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
1:26
The role of vaccines in AML
David Avigan • 26 Aug 2022
1:32
Calreticulin-directed vaccines how they may impact MPN treatment
Jean-Jacques Kiladjian • 22 Aug 2022
3:17
Dendritic cell/tumor fusion vaccine in transplant and CAR-T recipients
Poorva Bindal • 26 Apr 2022
1:25
Enhancing personalized therapeutic cancer vaccine development
Chiara Bonini • 1 Apr 2022
1:47
HemOnc vaccines: an update
Nina Shah • 31 Aug 2021
2:24
Immunotherapeutic approaches to myeloma
David Avigan • 13 Sep 2019
2:39
Vaccines to prevent progression or relapse in multiple myeloma
Ann van de Velde • 5 Oct 2018
4:24
PVX-410 vaccine for smoldering myeloma
Noopur Raje • 5 Oct 2018
1:20
Investigating vaccines for hem-onc: key questions
David Avigan • 5 Oct 2018
3:15
Dendritic cell vaccine for MM: Trial updates with maintenance & checkpoint inhibitor pidilizumab
David Avigan • 5 Oct 2018
The Immuno-oncology (I-O) Focus on VJHemOnc is supported by Johnson & Johnson. This supporter has no influence over the production of the content.

If you are interested in becoming a supporter of Immuno-oncology (I-O) Focus, please contact us.

The content of VJHemOnc is intended for healthcare professionals